

George William Creasy II

ADDRESS: 539 Brian Dean Drive **PHONE:** 908-537-4034
Glen Gardner, NJ 08826

EDUCATION:

1996-1997 Continuing Education, MBA Courses
Fairleigh Dickenson University

1980-1984 Residency in Obstetrics and Gynecology
York Hospital
York, Pennsylvania

1976-1980 Doctor of Medicine
The Pennsylvania State University

1972-1976 B.S. The Pennsylvania State University
Major: Pre-Medicine

CERTIFICATIONS:

Diplomat of the American Board of Obstetrics and Gynecology - 1986

LICENSURE:

Pennsylvania: MD-026179-E

EMPLOYMENT:

5/2014 – Present Medical Director
Population Council
Center for Biomedical Research
1230 York Avenue, NY, NY

10/2012 – 4/2014 NDA Director
Population Council
Center for Biomedical Research
1230 York Avenue, NY, NY

PAST POSITIONS:

5/11- 10/2012 Executive Officer of Columbia Laboratories, Inc.
11/03 – 10/2012 Vice President Clinical Research
Columbia Laboratories, Inc.
Plaza 1, Second Floor

Livingston, New Jersey

- 3/03 – 11/03 Sr. Director (Compound Development Leader/ Clinical Leader/
Strategic Development Leader)
Reproductive Health and Urology
Johnson & Johnson Pharmaceutical Research and
Development, LLD
920 Route 202, P.O. Box 300
Raritan, New Jersey
- 1/96 – 3/03 Director (Global Medical Leader/Safety Director)
Global Clinical Research & Development
Gynecology & Reproductive Research
Johnson & Johnson Pharmaceutical Research and
Development, LLD
920 Route 202, P.O. Box 300
Raritan, New Jersey
- 1/89 - 12/95 Associate Director
Clinical Research & Development
Gynecology & Reproductive Research
R. W. Johnson Pharmaceutical Research Institute
920 Route 202, P.O. Box 300
Raritan, New Jersey
- 2/87 - 1/89 Assistant Director
Clinical Research & Development
OB/GYN Therapeutics
R. W. Johnson Pharmaceutical Research Institute
Route 202
Raritan, New Jersey
- 7/84 - 2/87 Assistant Professor
Department of Obstetrics and Gynecology
The Milton S. Hershey Medical Center
The Pennsylvania State University
College of Medicine
Hershey, Pennsylvania

EMPLOYMENT-RELATED ACTIVITIES/COMMITTEES:

Medical Director (2012 – present) – In this position I have been responsible for the coordination of activities to file an NDA for novel contraceptive. In addition, I have a role in new clinical studies planned in both the Reproductive Health and HIV programs. I am serving as the responsible medical officer for new clinical studies and participating in crafting proposals, academic papers, regulatory submissions, project plans and protocols. In this role, I work with the pre-clinical and clinical teams from both Reproductive Health and HIV.

Vice President Clinical Research (2003-2012) – In this position I was responsible for Medical Affairs, Clinical Development of New Products, Drug Safety and Surveillance, and assist in acquiring and managing intellectual property. My responsibilities in Medical Affairs included review and approval of medical information letters (2003-2010), review and approval of drug labels and claims (2003-2010), review and approval of grants for investigator sponsored research (2003-2010), oversight and training of up to 4 MSLS (2007-2010), oversight of the CME expenses and activities (2003-2010).

Compound Development Team Leader –EVRA / Clinical Leader- EVRA/ Strategic Development Leader Women's Health and Urology (2003): In this position I was responsible for the R&D support of the global commercialization of EVRA as well as supporting the future growth of the reproductive franchise.

Clinical Safety Director (2001-2002): In this position I was responsible for the process to integrate safety data between Drug Safety and Surveillance and Clinical Operations for a drug that is both marketed and in clinical development by 3 Clinical Operations teams. My team consists of a team leader, a programmer, a statistician, and 2 MD clinical scientists (direct reports), and an MD safety officer.

Global Medical Leader – EVRA (1996-2002): In this position I have supervised and directed all of the medical aspects of global clinical development including: clinical program strategy, design and implementation; protocol writing; data collection and review; data analysis; report writing; and product message development. In this role I was a key member of the Global Product Team (for program development strategy) as well as a key member of the Operations Leadership Team (for program implementation). As such, I had close collaboration with drug safety personnel, regulatory personnel, statisticians, medical expert consultants, and business development personnel. In addition, I had matrix responsibility for the medical/safety aspects of the activities of one or more individuals in the following areas- protocol writing, forms design, data review, site monitoring, and medical writing. I interacted as needed with regulatory authorities worldwide on the medical aspects of projects that were my responsibility as well as with the investigators who conduct our studies.

Direct Reports: Depending on project size and load, have supervised up to 2 MDs, 2 project managers, 12 CRAs and 3 secretaries.

Project Team Leader: Have been project team leader for the TERAZOL project (1990-1991).

Medical Affairs Development Team Leader: Responsible for coordinating the efforts of all functional areas in Clinical Research so that the preterm labor project goals were completed on time and within budget (1994 -1996). This represented 14 additional dotted-line reports from Forms Design, Data Review, Data Entry, Programming, Biostatistics, Database Management, Medical Writing, Drug Metabolism, Regulatory Affairs, Clinical QA, Labelling, Clinical Supply, Finance, and Grants & Contracts.

Multicenter Study Coordination: Created a large perinatal network and coordinated the efforts of 70 academic perinatologists and their collective support of at least 150 nurses, pharmacists, residents and fellows in a preterm labor drug development effort (1993 - 1996). This included 4 hospitals in Santiago, Chile and one in the Dominican Republic. This project also involved 2 CRO's and a National Home Health company.

I have been part of a number of reprocessing efforts over the past 15 years. In some cases as part of the core reprocessing team (redesign of internal data tracking/handling), in other cases as part of the pilot implementation team (redesign of data entry/clean-up process).

I have also been the champion for the integration of technology solutions into the clinical development process through the development of a "home-page" for use with clinical sites/investigators. The home page is designed to save time and reduce costs by facilitating communications with investigators that previously either did not exist or took considerable time to complete.

PROFESSIONAL ORGANIZATIONS, COMMITTEES, AND ACTIVITIES:

1987	Fellow of the American College of Obstetricians and Gynecologists
1990	American Fertility Society

DRUG DEVELOPMENT:

Project Responsibilities as medical director including all necessary FDA meetings and presentations:

- Progesterone vaginal gel to prevent preterm delivery (2003- 2012)
- Lidocaine vaginal gel for dysmenorrhea (2003- 2010)
- Striant testosterone buccal delivery system (2003- 2011)
- Transdermal Contraceptive, hormonal (1997-2002)
- Oral Contraceptive, hormonal (1997-2002)
- Atosiban, tocolytic (1987-1997)
- Estrogen replacement program (1990-1993)
- IUD (1992-1993)
- SULTRIN[®], vaginal therapeutic (1987-1993)
- Gonadorelin acetate, GnRH replacement therapy (1990-1992)
- Histrelin, GnRH agonist (1989-1992)
- Phentolamine for male erectile dysfunction (1990-1992)
- Terconazole, vaginal antifungal (1987-1991)
- Recombinant human erythropoietin compassionate use (1988-1990)

Orphan Drug Applications:

- Pregnancy

IND's Filed:

- MIV-150/Zinc/Carrageenan vaginal gel for the prevention of HIV;
Lidocaine for dysmenorrhea;
Progesterone for the prevention of Preterm Birth;
Atosiban for preterm labor;
Pentolamine for erectile dysfunction

NDA's/SNDA's Filed:

- Progesterone Gel 8%, prevention of preterm birth
- EVRA, contraceptive patch
- ORTHO Tri-Cyclen Lo, oral contraceptive
- Antocin, tocolytic
- Monistat Tampons
- TERAZOL[®] 3-Day Cream
- Combination hormone replacement NDA

MAA's Filed:

- EVRA, contraceptive patch

Patents

- Progesterone for the prevention of preterm birth, patent # 7,884,093 issued 8 Feb 2011

GWC

5

16 May, 2014

FDA Advisory Committee Presentations:

- Atosiban Advisory Committee, April 20, 1998
- Prochieve Advisory Committee, January 20, 2012

FDA/NIH WORKSHOP PARTICIPATION:

October, 1989	Contraceptive Development Branch Workshop on LHRH Analogs "The View from The Pharmaceutical Industry"
November, 1989	Food and Drug Administration Antifungal and Acne Drug Product Bioequivalence Workshop "Consideration for Bioequivalence of Vaginal Antifungal Drug Products - Pioneer Industry Viewpoint".
March, 1995	"Difficulties in Preventing Pregnant Women from Entering Clinical Trials", General Clinical Research Directors Annual Meeting (NIH).

PUBLICATIONS AND PRESENTATIONS:

RESEARCH AND PUBLICATIONS:

1. Lipton, A., Kepner, N. and Creasy, G.W. Platelets as a source of cell proliferation activity, in Platelets: A Multidisciplinary Approach, G. Degaetano and S. Garattini (eds). New York: Raven Press; 1978.
2. Creasy, G.W. Letter to the Editor -- regarding article on "Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 62(3):397- 398; 1983.
3. Creasy, G.W., Kousen, M., and Walker, W.R. A zomepirac reaction mimicking ectopic pregnancy. Drug Intelligence and Clinical Pharmacy 18:487-488; 1984.
4. Creasy, G.W. and Simon, N.V. Sensitivity and specificity of the L/S ratios in relation to gestational age. Am J Perinatology 1(4):302- 305; 1984.
5. Lipton, A., and Creasy, G.W. An attempt to identify the source of fibroblast migration activity and growth activity noted in serum. (unpublished)
6. Creasy, G.W. Sensitivity and specificity. (Letter to the Editor) Obstet Gynecol 65(2):297; 1985.
7. Simon, N.V., Levinsky, J.S., Elser, R.D., Creasy, G.W. Prediction of fetal lung maturity by fluorescence polarization of amniotic fluid before 38 weeks of gestation. Influence of gestational age. Obstet Gynecol 65(3):346-351; 1985.
8. Creasy, G.W., Flickinger, F., Kraus, R.E. Maternal liver hemangioma of pregnancy as an incidental finding. Obstet Gynecol 66(3-S):1105-135; 1985.
9. Creasy, G.W. Antithrombin III activity in pregnant women with hypertension (Letter to the Editor) Obstet Gynecol 66(5):748; 1985.
10. Creasy, G.W., Levinsky, J.S. A review of obstetrical delivery and I.Q. Pennsylvania Medicine, 89(2):33-39; 1986.
11. Creasy, G.W., Morgan, J. Post-Ectopic nephrosclerosis. Obstet Gynecol 69:448; 1987.

12. Creasy, G.W. and Jaffe, M.E. Pulsatile delivery systems. The New York Academy of Sciences [1990].
13. Creasy, G.W. and Jaffe, M.E. Endocrine/Reproductive pulsatile delivery systems. Advanced Drug Delivery Reviews 6:51-56; 1991.
14. Worobec, S.M., Thorne, E.G. and Creasy, G.W. Topical Tretinoin and vaginal bleeding. Annals of Internal Medicine 1991.
15. Archer, D., Creasy, G.W., et. al. Endometrial morphology in asymptomatic postmenopausal women. Am. J. OB/GYN 165(2):317-322; 1991.
16. Creasy, G.W., Kafrissen, M.E. and Upmalis, D. A review of the endometrial effects of estrogens and progestins. OB/GYN Survey 47(9):654-678; 1992
17. Goodwin, T.M., Paul, R., Silver, H., Spellacy, W., Parsons, M., Chez, R., Hayashi, R., Valenzuela, G., Creasy, G.W., Merriman, R. The effect of the oxytocin antagonist Atosiban on preterm uterine activity in the human. Am. J. Obstet Gynecol. 170(2):474-478; 1994
18. Goodwin, T.M., Valenzuela, G., Silver, H., Hayashi, R., Creasy, G.W., Lane, R., Treatment of preterm labor with the oxytocin antagonist Atosiban, Am. J. of Perinatology, Vol. 13, No. 3., April 1996.
19. Goodwin, T.M., Valenzuela, G.J., Silver, H., Creasy, G., and the Atosiban Study Group. Dose Ranging Study of the Oxytocin Antagonist Atosiban in the Treatment of Preterm Labor. Obstetrics & Gynecology. 88 (3): 331-336; 1996.
20. Romero R , Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille J-C, Tabor B, Lane R, Smith J, Shangold G, Creasy G and the Atosiban PTL-096 Study Group. An Oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. The American Journal of Obstetrics & Gynecology. May 2000
21. Valenzuela GJ, Sanchez-Ramos L, Romero R, Silver HM, Koltun WD, Millar L, Wang J, Smith J, Creasy G, and the Atosiban PTL-098 Study Group. Maintenance Treatment of Preterm Labor with the Oxytocin Antagonist Atosiban. The American Journal of Obstetrics & Gynecology. May 2000

22. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC. Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. *Am J Obstet Gynecol* 2002;186:15-20, February
23. Audet M-C, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW . Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial. *JAMA* 2001;285:2347-2354.
24. Geoffrey H Smallwood, Mary L Meador, John P Lenihan Jr, Gary Shangold, Alan C Fisher, George Creasy and the EVRA 002 Study Group. Efficacy and Safety of a Transdermal Contraceptive System. *Obstetrics & Gynecology*: 2001: 98 (5): 799-805
25. LS Abrams, DM Skee, J Natarajan, FA Wong, PT Leese, GW Creasy, MM Shangold. Pharmacokinetics of a Contraceptive Patch (EVRA™/EVRA/ORTHO EVRA™) Containing Norelgestromin and Ethinyl Estradiol Under Conditions of Heat, Humidity, and Exercise; *J of Clin Pharmacol*, Vol 41, No 12, December 2001.
26. M Zieman, J Guillebaud, M Weisberg, G Shangold, A Fisher, G Creasy. A Summary of Contraceptive Efficacy and Cycle Control With the ORTHO EVRA™/EVRA™ Transdermal System. *Fertility and Sterility*; Vol 77, No 2, Supplement 2, February 2002.
27. BM Sibai, V Odland, M Meador, G Shangold, A Fisher, G Creasy. A Comparative and Pooled Analysis of the Safety/Tolerability of the Contraceptive Patch (ORTHO EVRA™/EVRA™). *Fertility and Sterility*; Vol 77, No 2, Supplement 2, February 2002.
28. D Archer, A Bigrigg, G Smallwood, G Shangold, G Creasy, A Fisher. Assessment of Subject Compliance With a Weekly Contraceptive Patch (ORTHO EVRA™/EVRA™) in North American Women. *Fertility and Sterility*; Vol 77, No 2, Supplement 2, February 2002.
29. H Zacur, B Hedon, D Mansour , G Shangold, A Fisher, G Creasy. Integrated Summary of ORTHO EVRA/EVRA Contraceptive Patch Adhesion in Varied Climates and Conditions. *Fertility and Sterility*; Vol 77, No 2, Supplement 2, February 2002.
30. Abrams L, Creasy G, Fisher A. Transdermal Contraception. *Seminars in Reproduction and Endocrinology*; Vol 19, No 4, December 2001

31. Raymond Moss Hampton, Marilyn Short, Eric Bieber, Celine Bouchard, Normand Ayotte, Gary Shangold, Alan C. Fisher and George W. Creasy. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20, *Contraception*, Volume 63, Issue 6, pages 289-295.
32. Creasy GW, Fisher A, Hall N, Shangold G. Effects of a transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol (Ortho Evra/Evra) on lipid profile. *The Journal of Reproductive Medicine*, 2003; 48:179-186.
33. Archer DF, Cullins V, Creasy GW, et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. *Contraception (United States)*, Mar 2004, 69(3) p189-95.
34. Elkind-Hirsch K, Darensbourg C, Creasy G, Gipe D. Conception rates in clomiphene citrate cycles with and without hormone supplementation: a pilot study. *Curr Med Res Opin*. 2005;21(7):1035-1040.
35. O'Brien JM, Adair CD, Lewis DF, Hall DR, DeFranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007; 30:687-696.
36. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007; 30:697-705.
37. O'Brien JM, DeFranco EA, Adair CD, Lewis DF, Hall DR, How H, Bsharat M, Creasy GW. Effect of Progesterone on Cervical Shortening in Women at Risk for Preterm Birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2009; vol 34.

38. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter J, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pilay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko d, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW, for the PREGNANT Trial. Vaginal Progesterone Reduces the Rate of Preterm Birth in Women with a Sonographic Short Cervix: a multi-center, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2011, Vol 38 No 1.
39. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Fonseca E Da, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan S. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. *American Journal of Obstetrics and Gynecology*, 2012, Vol 206, No 2.
40. Agustin Conde-Agudelo, MD, MPH, Roberto Romero, MD, DMedSci, Kypros Nicolaides, MD, Tinnakorn Chaiworapongsa, MD, John M. O'Brien, MD, Elcin Cetingoz, MD, Eduardo da Fonseca, MD, George Creasy, MD, Priya Soma-Pillay, MD, Shalini Fusey, MD, Cetin Cam, MD, Zarko Alfirevic, MD, Sonia S. Hassan, MD. Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. *American Journal of Obstetrics and Gynecology*, 2012, Vol 208, No 1.

ABSTRACTS:

1. Creasy GW, and Jaffe ME. Pulsatile delivery systems. The New York Academy of Sciences [1990].
2. Hahn DW, Demarest KT, Creasy GW, et. al. Pharmacology, toxicology, and pharmacokinetic profile of RWJ 22164 (1-Deamino-[D-TYR(OETHyl)²,Thr⁴, ORN⁸]) vasotocin, an oxytocin antagonist for treatment of preterm labor. Society for Gynecologic Investigation [1990].
3. Archer D, Creasy GW, et. al. Endometrial morphology in asymptomatic postmenopausal women. South Atlantic Association of Obstetrics and Gynecology [1991].
4. Goodwin TM, Paul R, Silver H, Valenzuela V, Depp R, Knuppel R, Renfroe Y, Creasy R, Creasy G, etc. Dose ranging study of oxytocin antagonist ANTOCIN \square (atosiban) and comparison to ritodrine. Abstract presented at ACOG 42nd Annual Clinical Meeting; [1994]
5. Sibai BM, Romero R, Sanchez-Ramos L, Valenzuela G, Veille JC, Tabor B, Morrison J, Varner M, Goodwin T, Menard K, Lane R, Smith J, and Creasy G, A Double-Blind Placebo-Controlled Trial of an Oxytocin-Receptor Antagonist (ANTOCIN) in the Treatment of Preterm Labor. Am. J. Obstet. Gynecol. 176 (1) Part 2: S2 (#2).
6. Silver H, Valenzuela G, Sanchez-Ramos L, Romero R, Sibai B, Goodwin T, Veille JC, Smith L, Shangold G, Creasy G, and the ANTOCIN study groups, Maternal Side Effects and Safety of the Oxytocin Receptor Antagonist ANTOCIN. Am. J. Obstet. Gynecol. 176 (1) Part 2: S45 (#124).
7. Sanchez-Ramos L, Valenzuela G, Romero R, Silver H, Koltun W, Millar L, Wang J, Smith J, Creasy G, and the Antocin PTL-098 Study Group, A Double-Blind Placebo-Controlled Trial of Oxytocin Receptor Antagonist (ANTOCIN) Maintenance Therapy in Patients with Preterm Labor. Am. J. Obstet. Gynecol. 176 (1) Part 2: 530 (#69).
8. Goodwin TM, Randall H, Perry K, Menard MK, Bauer C, Shangold G, Lane R, Creasy G and the Atosiban Study Group. A Report on Infant Outcomes at 6 and 12 Months after the use of Atosiban in the Management of Preterm Labor. 46th Annual Meeting of ACOG. Abstract/Poster #049.

9. Pierson RA, Hess AR, Archer DF, Parsons K, Shangold G, Fisher A, Creasy G. Effects of a contraceptive patch and 3 oral contraceptives on follicular development following incorrect dosing. *Int J Gyn Obstet* 2000;70 (suppl 1):78. Abstract.
10. Hedon B, Helmerhorst FM, Cronje HS, Shangold G, Fisher A, Creasy G. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch vs an oral contraceptive. *Int J Gyn Obstet* 2000;70(suppl 1):78. Abstract.
11. Guillebaud JG, Odlind V, Leonhardt K, Creasy G, Fisher A, Shangold G. Efficacy, cycle control, compliance, and safety in users of a contraceptive patch. *Int J Gyn Obstet* 2000;70(suppl 2):B77. Abstract.
12. Creasy G, Fisher A, Hall N, Shangold G. Effect of a contraceptive patch vs. placebo (PBO) on serum lipid profile. *Fertil Steril* 2000;74:S185. Abstract.
13. Kluff C, Mayer G, Helmerhorst FM, Hall H, Creasy G. Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters. *Int J Gyn Obstet* 2000;70(suppl 1):77. Abstract.
14. Thorne EG, Roach J, Hall J, Creasy G. Lack of phototoxicity and photoallergy with a contraceptive patch. *FASEB J* 2000;14:A1341. Abstract.
15. Creasy, G., Hall, N., Shangold, G. Patient Adherence With Evra™ Dosing Schedule Versus Oral Contraceptive (002/003/004) *Obstet & Gynecol* 2000;95(4)(suppl):60S
16. Creasy G, Fisher A, Hall N, Shangold G, Effects Of A Contraceptive Patch Versus Placebo On Serum Lipid Profile ; *Fertility & Sterility* 2000:74(3S):S185 DF
17. Archer, Koltun WD, G Shangold, G Creasy, A Fisher A Comparison of Patient Compliance With a Weekly Contraceptive Patch (ORTHO EVRA/EVRA) vs Oral Contraceptives (Ocs); *Journal of Managed Care Pharmacy* 2001:7(5);355-356
18. H Zacur, B Hedon, D Mansour, G Shangold, A Fisher, G Creasy Integrated Summary Of Ortho Evra/Evra Contraceptive Patch Adhesion in Varied Climates & Conditions; *Fertility & Sterility* 2001:76(3S);S19

19. Sibai, V Odlind, M Meador, G Shangold, A Fisher, G Creasy A Comparative Assessment of Ortho Evra/Evra to Placebo Path Effects on Body Weight; *Fertility & Sterility* 2001:76(3S);S188
20. M Zieman, J Guilleband, M Weisberg, G Shangold, Afisher, G Creasy Integrated Summary of Contraceptive Efficacy with the Ortho Evra/Evra Transdermal System; *Fertility & Sterility* 2001:76(3S); S19
21. D Archer, A Bigrigg, G Smallwood, G Shangold, G Creasy, A Fisher An Integrated Assessment of Patient Compliance with a Weekly Contraceptive Patch (Ortho Evra/Evra from North American Trials; *Fertility & Sterility* 2001:76(3S); S20
22. Creasy G et al. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on lipid profile. *J Rep Med* 2003;48:179-186.
23. DeZiegler D, Bulletti C, Palagiano A, Pace MC, Izzo A, and Creasy G. Pretreating with vaginal lidocaine reduces induced uterine contractions and pain in chronic dysmenorrhea. *Obstet & Gynecol* 2005;105(4S):68s-69s.
24. O'Brien JM, DeFranco EA, Adair CD, Lewis DF, Hall DR, Bsharat M, How H, Creasy GW, The Progesterone Vaginal Gel Study Group. Progesterone Reduces the Rate of Cervical Shortening in Women at Risk for Preterm Birth: Secondary Analysis from a Randomized, Double-blind, Placebo-Controlled Trial. *Am J Ob & Gynecol* 2007; Vol 197, No 6 (Supp): Abst 15, page S7.
25. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Phillips J, Creasy GW, The Progesterone Vaginal Gel Study Group. Is There a Racial Disparity in the Efficacy of Progesterone to Prevent Preterm Birth? *Am J Ob & Gynecol* 2007; Vol 197, No 6 (Supp): Abst 702, page S200.
26. O'Brien JM, Adair CD, Lewis DF, DeFranco EA, Phillips J, Creasy GW, The Progesterone Vaginal Gel Study Group. Does the Timing of Initial Progesterone dosing Alter the Utility of Progesterone Supplementation? Secondary Analysis from the the Progesterone Vaginal Gel Trial. *Am J Ob & Gynecol* 2007; Vol 197, No 6 (Supp): Abst 725, page S206.

27. O'Brien JM, Steichen JJ, Phillips JA, Creasy GW. Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Am J Ob & Gynecol 2012; Vol 206, No 1 (Supp): Abst 490, page S223.
28. Creasy GW, Brache V, Croxatto H, Mishell DR, Kumar N, Roberts K, Merkatz R, Sitruk-Ware R, User Controlled Long Acting Reversible Contraception: The Pharmacokinetic Profile of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR) a 1-Year Cyclical Re-useable Vaginal Ring. 2013 International Conference on Family Planning. <http://www.xcdsystem.com/ICFP2013/abstract/pdfpresentations/Res662.pdf>

ACADEMIC TOPICS PRESENTED:

Part of my duties as Medical Monitor of multicenter trials has been to present at investigator meetings, product advisory boards, grand rounds and conferences. Many such presentations have been made.

As Vice President and Executive Officer at Columbia Laboratories, I have also made many presentations to the Board of Directors. I have also presented on several occasions to share-holders.

DEVELOPMENT AND TRAINING

10/20-10/25/91	Leadership Development Program Hartford Graduate Center Hartford, CT
1/96	Review of Probability and Statistics, Fairleigh Dickenson University (FDU).
2/96-5/96	Production and Operation Planning (QBA), FDU.
9/96-12/96	Strategic Analysis and Organizational Design, FDU.
2/97-5/97	Economic Analysis, FDU
11/3-6/2002	Kellogg School of Management: Leading High Impact Teams